-
Evolution of Dosimetric Parameters Through PRRT: Insights from the Phase II LUMEN Study
The phase II LUMEN study explores the dynamic changes in dosimetric parameters during Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTA-TATE for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study reveals significant variability in absorbed doses and activity concentrations, particularly when comparing tumor sites to organs-at-risk such as the kidneys and red marrow. In pancreatic NETs,…
-
Targeting HER2 in Gastroesophageal Cancer: A New Approach to an Ongoing Challenge
The incidence of gastroesophageal cancers is on the rise, driven by factors such as obesity and gastroesophageal reflux. Despite increased awareness and screening efforts, many cases are diagnosed at an advanced, unresectable stage, making effective systemic treatments critical for improving survival and quality of life.
-
Comparing Entecavir and Tenofovir Alafenamide in Chronic Hepatitis B: A Long-Term Observational Study
In January 2025, Scientific Reports published an observational pilot study evaluating the long-term efficacy and safety of entecavir (ETV) versus tenofovir alafenamide (TAF) in patients with chronic hepatitis B.Key Findings:After…
-
Consensus on Clinical Trial Design for Acute Severe Ulcerative Colitis (ASUC)
A new international Delphi consensus led by valuable researchers provides crucial guidance on the design and endpoints of clinical trials for Acute Severe Ulcerative Colitis (ASUC). This comprehensive consensus, developed with input from global experts, establishes 30 key statements that define essential aspects of ASUC trial design.
-
Spotlight on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
A recent publication in Gastroenterology provides an in-depth overview of the latest guidelines for the pharmacological management of moderate-to-severe ulcerative colitis (UC). The evolving landscape of UC treatment highlights the importance of personalized approaches, balancing efficacy, safety, and patient preferences.
-
Preventing MASLD-Related Hepatocellular Carcinoma: Insights from Clinical Gastroenterology and Hepatology
In January 2025, Clinical Gastroenterology and Hepatology published a narrative review titled “Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma.”With MASLD (Metabolic Dysfunction-associated Steatotic…
-
Unveiling a New Perspective on Colorectal Cancer: The Role of Unresolved Inflammation
A recent study published in Gut offers groundbreaking insights into colorectal cancer (CRC), revealing that the disease may persist in a state of chronic, unresolved inflammation, akin to a poorly healing wound. Researchers utilized advanced techniques, including lipidomics, single-cell, and spatial transcriptomics, to identify a critical imbalance within the tumor microenvironment.
-
INTEGRATE IIa Phase III Study: Regorafenib Shows Survival Benefits in Refractory Advanced Gastric Cancer
Valuable researchers have delivered promising results from the INTEGRATE IIa Phase III trial, evaluating regorafenib, an oral multikinase inhibitor, in patients with refractory advanced gastric and esophagogastric junction cancer (AGOC).
Connecting Medical Expertise through Media